Northrop Grumman, Luminex collaborate on autonomous biodetectors

Published 17 March 2010

Luminex’s xMAP Technology will serve as the basis of the two companies’ effort to develop a fully automated biosensor which will continuously monitor the environment and serve as an early warning system to alert authorities regarding the release of potentially harmful airborne agents

Austin, Texas-based Luminex Corporation (Nasdaq: LMNX) has signed a teaming agreement with Northrop Grumman Corporation (NYSE: NOC) to collaborate in the creation of next generation biodetectors which will continuously monitor the environment and serve as an early warning system to alert authorities regarding the release of potentially harmful airborne agents.

Under the terms of the agreement, the two companies will work together to develop a new fully autonomous biological detection system. The system is being developed for evaluation by the U.S. government as part of a national network of fully automated environment monitoring devices.

When it comes to environmental detection of biological pathogens, fast and accurate answers are essential,” said David Tilles, vice president of CBRNE Defense at Northrop Grumman’s Advanced Concepts & Technologies Division. “Luminex’s xMAP Technology gives us a cost-effective, flexible capability that can quickly and accurately detect multiple biohazards at once. This flexibility allows us to meet today’s requirements, and to adapt to future threats that may emerge.”

We are delighted to be collaborating with Northrop Grumman, a leader and innovator in the global security market,” said Patrick J. Balthrop, president and CEO of Luminex Corporation. “The capabilities of our xMAP Technology are highly suited to applications such as monitoring for harmful pathogens where speed, accuracy and definitive, actionable answers are paramount.”

Luminex’s xMAP Technology will allow the next generation biodetectors to run many simultaneous tests on a single sample. xMAP Technology is used in scientific research, drug discovery and clinical diagnostics, as well as in biodefense and agro-biotechnology. To date, more than 6,700 Luminex instruments have been placed in labs and clinics worldwide, and over 50 products based on this technology have been cleared by FDA.